One capsule contains: 250 mg of the active ingredient - Gamma-Aminobutyric acid. Inactive ingredients: 27.2 mg sucrose and 2.8 mg magnesium stearate monohydrate. Coating: 85.92 mg magnesium hydroxide carbonate (magnesium carbonate base) and 17.26 mg wheat flour.
Aminalon is a nootropic which restores metabolic processes in the brain, regulates the brain's use of glucose, and works to remove metabolic toxins. It improves thinking, memory, and restores motor and speech functions after problems caused by insufficient blood flow to the brain. It has a light tension booster effect, and lowers arterial pressure and alleviates symptoms of hypertonia (dizziness and insomnia). GABA slightly reduces heart rate. It also has a moderate anti-hypoxic and anticonvulsant effect. It lowers glucose levels in people with diabetes and produces the opposite effect in those with normal glucose levels.
Absorption is quick and efficient. The TCmax is 60 minutes, then the concentration quickly lowers. After 24 hours it is not detectable in plasma.
Administration and dose:
To be taken orally after a meal. The daily dose for adults is 3-3.75 grams. For children (1-3 year-olds) –– 1-2 grams daily; (4-6 year-olds) - 2-3 grams daily; (children over seven years old) - 3 grams daily. The full daily amount should be taken in three separate doses. The treatment can last from 2-3 weeks to 2-4 months. Adults should take 0.5 grams for prevention or aleviation of seasickness. For children, the dose is 0.25 grams, taken three times a day, for 3-4 days.
GABA increases the effects of benzodiazepines, certain sleeping pills, and epilepsy medications.
Aminalon is not recommended for patients with acute kidney and liver disease.
Aminalon is a substance with nootropic and psychostimulatory qualities. Gamma-Aminobutyric acid is the only active component in this drug. Aminalon (C4H9NO2) is a neurotransmitter which slows nerve impulse. Gamma-Aminobutyric acid (also known as GABA, γ-aminobutyric acid) is synthesised in the brain from glutamic acid (another neurotransmitter) through decarboxylation (a chemical reaction that removes a carboxyl group and releases carbon dioxide).
Researchers discovered Gamma-Aminobutyric acid in 1950. It was marketed in Japan in the 1960’s under the name Gammalon. The drug then appeared in the USSR in the 1970’s as Aminalon.
The main property of GABA is that it regulates blood flow in the brain, improves memory, speech, and coordination. It increases oxygen levels in nerve tissue and protects against convulsions. GABA facilitates absorption of glucose. It can also lower blood pressure, regulate sleep, and remove toxic metabolites.
Indications for use:
Aminalon is indicated for children for:
As mentioned above, the active component of Aminalon is Gamma-Aminobutyric acid (GABA). It facilitates cerebral metabolic processes. It works thanks to the interaction between its active element and specific receptors in the brain. As a result, blood flow to the brain normalises, as well as cellular respiration and energy production. GABA works to remove toxic substances and harmful metabolic products while regulating the body's use of glucose. This leads to an overall regulation of CNS processes. The patient experiences improved memory and thinking as well as recovery of speech and motor skills lost due to reduced blood flow to the brain. Additionally, the active component of the drug stabilises arterial pressure, alleviating unpleasant symptoms such as interrupted sleep, vertigo, and convulsions. Patients suffering from diabetes notice lowered blood sugar after taking the drug.
- J Kardos (1999) Recent advances in GABA research https://www.ncbi.nlm.nih.gov/pubmed/10397362
- B Lydiard (2003) The role of GABA in anxiety disorders https://www.ncbi.nlm.nih.gov/pubmed/12662130
- Wassef et al (2003) GABA and schizophrenia: a review of basic science and clinical studies https://www.ncbi.nlm.nih.gov/pubmed/14624191
- Abdou et al (2006) Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans https://www.ncbi.nlm.nih.gov/pubmed/16971751
- N Bowery, T Smart (2006) GABA and glycine as neurotransmitters: a brief history https://www.ncbi.nlm.nih.gov/pubmed/16402094
- Tyagi et al (2007) Differential expression of gamma-aminobutyric acid receptor A (GABA(A)) and effects of homocysteine https://www.ncbi.nlm.nih.gov/pubmed/17990949
- Powers et al (2008) Growth hormone isoform responses to GABA ingestion at rest and after exercise https://www.ncbi.nlm.nih.gov/pubmed/18091016
- Appel et al (2011) Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L https://www.ncbi.nlm.nih.gov/pubmed/21089181
- Plante et al (2012) The Role of GABA in Primary Insomnia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353037/
- Shi et al (2014) Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023459/
- Boonstra et al (2015) Neurotransmitters as food supplements: the effects of GABA on brain and behavior https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594160/
- P Nuss (2015) Anxiety disorders and GABA neurotransmission: a disturbance of modulation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303399/
- Steenbergen et al (2015) γ-Aminobutyric acid (GABA) administration improves action selection processes: a randomised controlled trial
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639630/ Li et al (2015) Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521208/
- Zhang et al (2016) Brain Gamma-Aminobutyric Acid (GABA) Concentration of the prefrontal lobe in unmedicated patients with obsessive-compulsive disorder: a research of magnetic resonance spectroscopy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434282/
- Wu et al (2016) GABA receptors in brain development, function, and injury https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231020/
- Savage et al (2018) GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence https://www.ncbi.nlm.nih.gov/pubmed/29168225
- Cuypers et al (2018) Aging and GABA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046222/